Conference call and webcast to be held at
4:30 p.m. ET
NEW
HAVEN, Conn., Oct. 30,
2024 /PRNewswire/ -- Trevi Therapeutics,
Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for the treatment of chronic cough in idiopathic
pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today
announced that senior management will host a conference call and
live audio webcast on Wednesday, November 6,
2024, at 4:30 p.m. ET, to
provide a corporate update and review the Company's financial
results for the quarter ended September 30,
2024.
To participate in the live conference call by phone, please dial
(877) 870 4263 (domestic) or (412) 317 0790 (international) and ask
to join the Trevi Therapeutics call. No code is necessary for
access. A live audio webcast will be accessible from the 'Investors
& News' section on the Company's website at
www.TreviTherapeutics.com. An archived replay of the webcast will
also be available for 30 days on the Company's website following
the event.
About Trevi Therapeutics, Inc.
Trevi
Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing the investigational therapy
Haduvio™ (oral nalbuphine extended-release (ER))
for the treatment of chronic cough in idiopathic pulmonary fibrosis
(IPF) and refractory chronic cough
(RCC). Haduvio acts on the cough reflex
arc both centrally and peripherally as a kappa agonist
and a mu antagonist (KAMA), which are
opioid receptors that play a key role in controlling cough
hypersensitivity. Nalbuphine is not scheduled by the
U.S. Drug Enforcement Agency.
The impact of chronic cough is significant and often leads to a
decline in patients' social, physical, and psychological quality of
life. In IPF, chronic cough may lead to worsening disease and may
be associated with a higher risk of progression, death, or need for
lung transplant. There are no approved therapies for the treatment
of chronic cough in IPF and current treatment options provide
minimal benefit to patients. Chronic cough affects up to 10% of the
adult population, and Haduvio's expansion into RCC has the
potential to reach patients suffering from moderate to severe
refractory chronic cough. There are also no approved therapies for
RCC in the U.S.
Trevi intends to propose Haduvio as the trade name for oral
nalbuphine ER. Its safety and efficacy have not been evaluated by
any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie Barrett
Trevi Therapeutics,
Inc.
203-304-2499
k.barrett@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-third-quarter-2024-financial-results-and-provide-a-corporate-update-on-november-6-2024-302291657.html
SOURCE Trevi Therapeutics, Inc.